INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 55 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2014. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $444,834,276 | -17.3% | 8,539,725 | +0.5% | 0.01% | -15.4% |
| Q2 2023 | $537,969,000 | +17.7% | 8,496,036 | +0.6% | 0.01% | +8.3% |
| Q1 2023 | $457,196,951 | +3.8% | 8,443,157 | +1.5% | 0.01% | 0.0% |
| Q4 2022 | $440,254,657 | +16.6% | 8,319,249 | +2.5% | 0.01% | +9.1% |
| Q3 2022 | $377,638,000 | -18.1% | 8,116,020 | +0.4% | 0.01% | -15.4% |
| Q2 2022 | $461,218,000 | -3.2% | 8,080,198 | +3.7% | 0.01% | +18.2% |
| Q1 2022 | $476,577,000 | +32.4% | 7,788,469 | +13.3% | 0.01% | +37.5% |
| Q4 2021 | $359,901,000 | +40.1% | 6,876,201 | -0.2% | 0.01% | +33.3% |
| Q3 2021 | $256,918,000 | -7.8% | 6,891,569 | +0.9% | 0.01% | -14.3% |
| Q2 2021 | $278,737,000 | +22.2% | 6,828,437 | +1.6% | 0.01% | +16.7% |
| Q1 2021 | $228,067,000 | +10.7% | 6,721,693 | +3.7% | 0.01% | 0.0% |
| Q4 2020 | $206,108,000 | +28.9% | 6,481,344 | +4.0% | 0.01% | +20.0% |
| Q3 2020 | $159,844,000 | +18.1% | 6,229,298 | +18.2% | 0.01% | 0.0% |
| Q2 2020 | $135,293,000 | +67.4% | 5,270,444 | +0.2% | 0.01% | +66.7% |
| Q1 2020 | $80,844,000 | -44.2% | 5,259,830 | +24.7% | 0.00% | -40.0% |
| Q4 2019 | $144,774,000 | +363.4% | 4,219,590 | +0.9% | 0.01% | +400.0% |
| Q3 2019 | $31,241,000 | -42.6% | 4,182,130 | -0.2% | 0.00% | -50.0% |
| Q2 2019 | $54,388,000 | +5.9% | 4,190,181 | -0.6% | 0.00% | 0.0% |
| Q1 2019 | $51,357,000 | +14.6% | 4,216,535 | +7.2% | 0.00% | 0.0% |
| Q4 2018 | $44,806,000 | -47.6% | 3,933,930 | -0.3% | 0.00% | -33.3% |
| Q3 2018 | $85,580,000 | +25.0% | 3,943,792 | +1.8% | 0.00% | 0.0% |
| Q2 2018 | $68,452,000 | -13.0% | 3,873,842 | +3.6% | 0.00% | 0.0% |
| Q1 2018 | $78,699,000 | +45.7% | 3,738,677 | +0.2% | 0.00% | +50.0% |
| Q4 2017 | $54,013,000 | -1.3% | 3,730,258 | +7.6% | 0.00% | -33.3% |
| Q3 2017 | $54,697,000 | +61.8% | 3,466,253 | +27.4% | 0.00% | +50.0% |
| Q2 2017 | $33,804,000 | -24.1% | 2,721,732 | -0.7% | 0.00% | 0.0% |
| Q1 2017 | $44,556,000 | +15.5% | 2,741,887 | +7.3% | 0.00% | 0.0% |
| Q4 2016 | $38,565,000 | +2.9% | 2,555,722 | +3.9% | 0.00% | 0.0% |
| Q3 2016 | $37,481,000 | -59.0% | 2,459,371 | +4.4% | 0.00% | -66.7% |
| Q2 2016 | $91,449,000 | +109.0% | 2,355,713 | +49.6% | 0.01% | +100.0% |
| Q1 2016 | $43,761,000 | -41.9% | 1,574,163 | +12.5% | 0.00% | -40.0% |
| Q4 2015 | $75,291,000 | -2.2% | 1,399,712 | -27.2% | 0.01% | +66.7% |
| Q3 2015 | $76,968,000 | +232.7% | 1,922,262 | +165.5% | 0.00% | +50.0% |
| Q2 2015 | $23,132,000 | +53.8% | 723,993 | +14.9% | 0.00% | +100.0% |
| Q1 2015 | $15,041,000 | +89.8% | 629,875 | +40.3% | 0.00% | 0.0% |
| Q4 2014 | $7,925,000 | +42.8% | 449,003 | +10.9% | 0.00% | – |
| Q3 2014 | $5,551,000 | -16.6% | 404,908 | +2.5% | 0.00% | -100.0% |
| Q2 2014 | $6,658,000 | +8.5% | 394,932 | +17.0% | 0.00% | 0.0% |
| Q1 2014 | $6,138,000 | – | 337,640 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |